Drug intelligence / Profile preview

placebo + paclitaxel + carboplatin

Development stage: Discontinued
Lead developer: Oncotelic Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

A combination regimen consisting of a placebo administered in conjunction with the chemotherapy drugs paclitaxel and carboplatin. This specific combination was utilized as the control arm in the Phase 3 FACT2 clinical trial (NCT01701349), sponsored by Mateon Therapeutics, which investigated the efficacy of adding fosbretabulin to standard chemotherapy for patients with anaplastic thyroid carcinoma. Paclitaxel functions as a microtubule stabilizer, while carboplatin acts as a DNA-alkylating agent. The trial aimed to compare the survival outcomes of patients receiving this control regimen against those receiving the experimental triplet therapy.

Other names: Placebo plus paclitaxel and carboplatin

Targets

TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on placebo + paclitaxel + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo + paclitaxel + carboplatin.

Explore the full profile